Situation: A leading international life sciences company had to explain in court why its settlement of patent litigation with a potential generic entrant was driven by legitimate business considerations.
CRA contribution: CRA assembled a team with expertise in the pharmaceuticals industry, antitrust analysis, and game theory. Our economic analysis of the settlement accounted for the business risks facing the parties as well as the potential for a delay in generic entry.
Result: CRA’s expert analysis supported the defendant’s pre-trial motions, which were successful in having the case dismissed.
CRA consultants named top IP strategists in IAM Strategy 300 2021
Robert Goldman, Daniel McGavock, Dr. Richard Razgaitis, and Larry Rosenberg were recognized in the latest edition of IAM Strategy 300 – The World’s Leading IP...